-
Je něco špatně v tomto záznamu ?
Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn)
J. Salmanton-García, D. Seidel, P. Koehler, SC. Mellinghoff, R. Herbrecht, N. Klimko, Z. Ráčil, I. Falces-Romero, P. Ingram, MÁ. Benítez-Peñuela, JY. Rodríguez, G. Desoubeaux, A. Barać, C. García-Vidal, M. Hoenigl, SR. Mehta, MP. Cheng, G....
Journal of antimicrobial chemotherapy.
2019 ;
74 (11) :
3315-3327.
[pub] 20191101
Jazyk angličtina Země Velká Británie
Typ dokumentu klinické zkoušky, časopisecké články, pozorovací studie, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc20025537
Online
Plný text
NLK
Free Medical Journals
od 1996 do Před 1 rokem
Open Access Digital Library
od 1996-01-01
PubMed
31393591
DOI
10.1093/jac/dkz344
Knihovny.cz E-zdroje
- MeSH
- amfotericin B terapeutické užití MeSH
- analýza párové shody MeSH
- antifungální látky aplikace a dávkování chemie MeSH
- dítě MeSH
- dospělí MeSH
- invazivní mykotické infekce farmakoterapie MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- Mucorales účinky léků MeSH
- mukormykóza krev farmakoterapie MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- příprava léků MeSH
- prospektivní studie MeSH
- registrace MeSH
- senioři MeSH
- triazoly aplikace a dávkování chemie MeSH
- Check Tag
- dítě MeSH
- dospělí MeSH
- kojenec MeSH
- lidé středního věku MeSH
- lidé MeSH
- mladiství MeSH
- mladý dospělý MeSH
- mužské pohlaví MeSH
- novorozenec MeSH
- předškolní dítě MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- klinické zkoušky MeSH
- pozorovací studie MeSH
- práce podpořená grantem MeSH
BACKGROUND: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. OBJECTIVES: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. METHODS: We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). RESULTS: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. CONCLUSIONS: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.
Clinical Microbiology and Parasitology Department University Hospital La Paz Madrid Spain
Department of Internal Medicine 2 Julius Maximilians University Würzburg Germany
Department of Internal Medicine 3 University of Munich Munich Germany
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20025537
- 003
- CZ-PrNML
- 005
- 20201222153941.0
- 007
- ta
- 008
- 201125s2019 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/jac/dkz344 $2 doi
- 035 __
- $a (PubMed)31393591
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Salmanton-García, Jon $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
- 245 10
- $a Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn) / $c J. Salmanton-García, D. Seidel, P. Koehler, SC. Mellinghoff, R. Herbrecht, N. Klimko, Z. Ráčil, I. Falces-Romero, P. Ingram, MÁ. Benítez-Peñuela, JY. Rodríguez, G. Desoubeaux, A. Barać, C. García-Vidal, M. Hoenigl, SR. Mehta, MP. Cheng, G. Klyasova, WJ. Heinz, N. Iqbal, R. Krause, H. Ostermann, O. Penack, E. Schalk, DC. Sheppard, B. Willinger, H. Wisplinghoff, JJ. Vehreschild, OA. Cornely, MJGT. Vehreschild, FungiScope® ECMM/ISHAM Working Group,
- 520 9_
- $a BACKGROUND: First-line antifungal treatment for invasive mucormycosis (IM) consists of liposomal amphotericin B. Salvage treatment options are limited and often based on posaconazole oral suspension. With the approval of posaconazole new formulations, patients could benefit from improved pharmacokinetics, safety and tolerability. OBJECTIVES: Our aim was to assess the effectiveness of posaconazole new formulations for IM treatment. METHODS: We performed a case-matched analysis with proven or probable IM patients from the FungiScope® Registry. First-line posaconazole new formulations (1st-POSnew) and first-line amphotericin B plus posaconazole new formulations (1st-AMB+POSnew) cases were matched with first-line amphotericin B-based (1st-AMB) treatment controls. Salvage posaconazole new formulations (SAL-POSnew) cases were matched with salvage posaconazole oral suspension (SAL-POSsusp) controls. Each case was matched with up to three controls (based on severity, haematological/oncological malignancy, surgery and/or renal dysfunction). RESULTS: Five patients receiving 1st-POSnew, 18 receiving 1st-AMB+POSnew and 22 receiving SAL-POSnew were identified. By day 42, a favourable response was reported for 80.0% (n = 4/5) of patients receiving 1st-POSnew, for 27.8% (n = 5/18) receiving 1st-AMB+POSnew and for 50.0% (n = 11/22) receiving SAL-POSnew. Day 42 all-cause mortality of patients receiving posaconazole new formulations was lower compared with controls [20.0% (n = 1/5) in 1st-POSnew versus 53.3% (n = 8/15) in 1st-AMB; 33.3% (n = 6/18) in 1st-AMB+POSnew versus 52.0% (n = 26/50) in 1st-AMB; and 0.0% (n = 0/22) in SAL-POSnew versus 4.4% (n = 2/45) in SAL-POSsusp]. CONCLUSIONS: Posaconazole new formulations were effective in terms of treatment response and associated mortality of IM. While posaconazole new formulations may be an alternative for treatment of IM, the limited sample size of our study calls for a cautious interpretation of these observations.
- 650 _2
- $a mladiství $7 D000293
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a amfotericin B $x terapeutické užití $7 D000666
- 650 _2
- $a antifungální látky $x aplikace a dávkování $x chemie $7 D000935
- 650 _2
- $a dítě $7 D002648
- 650 _2
- $a předškolní dítě $7 D002675
- 650 _2
- $a příprava léků $7 D004339
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a kojenec $7 D007223
- 650 _2
- $a novorozenec $7 D007231
- 650 _2
- $a invazivní mykotické infekce $x farmakoterapie $7 D000072742
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a analýza párové shody $7 D016555
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a Mucorales $x účinky léků $7 D009090
- 650 _2
- $a mukormykóza $x krev $x farmakoterapie $7 D009091
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a registrace $7 D012042
- 650 _2
- $a triazoly $x aplikace a dávkování $x chemie $7 D014230
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a pozorovací studie $7 D064888
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Seidel, Danila $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- 700 1_
- $a Koehler, Philipp $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany.
- 700 1_
- $a Mellinghoff, Sibylle C $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany.
- 700 1_
- $a Herbrecht, Raoul $u Department of Oncology and Hematology, Hôpitaux Universitaires de Strasbourg and Université de Strasbourg, Inserm, UMR-S1113/IRFAC, Strasbourg, France.
- 700 1_
- $a Klimko, Nikolai $u Department of Clinical Mycology, Allergy and Immunology, North Western State Medical University, Saint Petersburg, Russia.
- 700 1_
- $a Ráčil, Zdeněk $u Department of Internal Medicine-Hematology and Oncology, Masaryk University, Brno, Czech Republic. University Hospital Brno, Brno, Czech Republic.
- 700 1_
- $a Falces-Romero, Iker $u Clinical Microbiology and Parasitology Department, University Hospital La Paz, Madrid, Spain.
- 700 1_
- $a Ingram, Paul $u Department of Infectious Diseases, Royal Perth Hospital, Perth, WA, Australia. School of Pathology and Laboratory Medicine, University of Western Australia, Perth, WA, Australia.
- 700 1_
- $a Benítez-Peñuela, Miguel-Ángel $u Center of Microbiological Research of Cesar (CIMCE), Rosario Pumarejo de López Hospital, Laura Daniela Clinic, Médicos Clinic LTDA, Valledupar, Colombia.
- 700 1_
- $a Rodríguez, José Yesid $u Center of Microbiological Research of Cesar (CIMCE), Rosario Pumarejo de López Hospital, Laura Daniela Clinic, Médicos Clinic LTDA, Valledupar, Colombia.
- 700 1_
- $a Desoubeaux, Guillaume $u Parasitology, Mycology and Tropical Medicine Service, University Hospital of Tours, Tours, France. Inserm U1100, Tours University, Tours, France.
- 700 1_
- $a Barać, Aleksandra $u Clinic for Infectious and Tropical Diseases, Clinical Centre of Serbia, Faculty of Medicine, University of Belgrade, Serbia.
- 700 1_
- $a García-Vidal, Carolina $u Service of Infectious Diseases, Clínic Hospital, University of Barcelona, Institute of Biomedical Research August Pi i Sunyer, Barcelona, Spain.
- 700 1_
- $a Hoenigl, Martin $u Division of Infectious Diseases, University of California San Diego, San Diego, CA, USA. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Mehta, Sanjay R $u Division of Infectious Diseases, University of California San Diego, San Diego, CA, USA. Department of Medicine, San Diego Veterans Affairs Medical Center San Diego, CA, USA.
- 700 1_
- $a Cheng, Matthew P $u Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
- 700 1_
- $a Klyasova, Galina $u Department of Clinical Microbiology, Mycology and Antibiotic Therapy, National Research Center for Hematology, Moscow, Russia.
- 700 1_
- $a Heinz, Werner J $u Department of Internal Medicine II, Julius Maximilians University, Würzburg, Germany.
- 700 1_
- $a Iqbal, Nousheen $u Section of Pulmonology and Critical Care, Department of Medicine, Aga Khan University Hospital, Karachi, Pakistan.
- 700 1_
- $a Krause, Robert $u Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria.
- 700 1_
- $a Ostermann, Helmut $u Department of Internal Medicine III, University of Munich, Munich, Germany.
- 700 1_
- $a Penack, Olaf $u Department for Hematology, Oncology and Tumorimmunology, Charité University Medicine Berlin, Campus Virchow Clinic, Berlin, Germany.
- 700 1_
- $a Schalk, Enrico $u Department of Haematology and Oncology, Medical Centre, Otto-von-Guericke University Magdeburg, Magdeburg, Germany.
- 700 1_
- $a Sheppard, Donald C $u Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada.
- 700 1_
- $a Willinger, Birgit $u Division of Clinical Microbiology, Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.
- 700 1_
- $a Wisplinghoff, Hilmar $u University of Cologne, Institute for Medical Microbiology, Immunology and Hygiene, Cologne, Germany. Wisplinghoff Laboratories, Cologne, Germany. Institute for Virology and Clinical Microbiology, Witten/Herdecke University, Witten, Germany.
- 700 1_
- $a Vehreschild, J Janne $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany. German Centre for Infection Research (DZIF), partner site Bonn - Cologne, Cologne, Germany. Center for Integrated Oncology CIO Köln/Bonn, Medical Faculty, University of Cologne, Cologne, Germany.
- 700 1_
- $a Cornely, Oliver A $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany. Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne, Germany. German Centre for Infection Research (DZIF), partner site Bonn - Cologne, Cologne, Germany. Center for Integrated Oncology CIO Köln/Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Clinical Trials Centre Cologne (ZKS Köln), University of Cologne, Cologne, Germany. Center for Molecular Medicine Cologne (CMMC), University of Cologne, Cologne, Germany.
- 700 1_
- $a Vehreschild, Maria J G T $u University of Cologne, Faculty of Medicine and University Hospital of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), European Diamond Excellence Center for Medical Mycology (ECMM), Cologne, Germany. German Centre for Infection Research (DZIF), partner site Bonn - Cologne, Cologne, Germany. Center for Integrated Oncology CIO Köln/Bonn, Medical Faculty, University of Cologne, Cologne, Germany. Department of Internal Medicine, Infectious Diseases, Goethe University, Frankfurt, Frankfurt am Main, Germany.
- 710 2_
- $a FungiScope® ECMM/ISHAM Working Group
- 773 0_
- $w MED00002514 $t The Journal of antimicrobial chemotherapy $x 1460-2091 $g Roč. 74, č. 11 (2019), s. 3315-3327
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31393591 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20201125 $b ABA008
- 991 __
- $a 20201222153936 $b ABA008
- 999 __
- $a ok $b bmc $g 1599682 $s 1116223
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 74 $c 11 $d 3315-3327 $e 20191101 $i 1460-2091 $m Journal of antimicrobial chemotherapy $n J Antimicrob Chemother $x MED00002514
- LZP __
- $a Pubmed-20201125
